GlassScriptPhysician profile
Karen Perry
NPI 1659547354
$2,803.52
in general payments reported to CMS, 2019-2025
25 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $629 · 2022: $612 · 2023: $410 · 2024: $595 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $586.34 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $292.91 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Daiichi Sankyo INC. | $263.49 | 2021-2023 | Injectafer |
| Pfizer INC. | $235.41 | 2022-2025 | |
| Abbott Laboratories | $216.55 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $197.40 | 2022-2025 | |
| Astellas Pharma US INC | $122.37 | 2021-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.15 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $114.91 | 2021 | |
| Glaxosmithkline, LLC. | $112.72 | 2021-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $104.03 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $94.41 | 2021-2025 | Repatha, Otezla, Repatha |
| Nevro Corp. | $66.41 | 2021-2023 | Senza |
| Novartis Pharmaceuticals Corporation | $54.32 | 2021-2025 | |
| Exact Sciences Corporation | $39.45 | 2024 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $28.07 | 2025 | Sapien 3 Ultra Resilia |
| Phathom Pharmaceuticals, INC. | $26.14 | 2025 | Voquezna |
| Althera Pharmaceuticals LLC | $24.06 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $18.91 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.57 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.35 | 2021 | |
| Abbvie INC. | $14.28 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.82 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $13.51 | 2021 | |
| Medtronic, INC. | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.